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Abstract. Background: The 5-year survival rate of the oral
cancer patients has remained at approximately the 50% level
during the past 30 years, possibly due to the poor tumor-
selectivity of conventional anticancer drugs. This prompted us
to search new plant extracts that have higher cytotoxicity
against cancer cells than normal cells. Materials and
Methods: Two human oral squamous cell carcinoma cell lines
(HSC-2 and HSC-4) and two normal oral cells (gingival and
periodontal ligament fibroblasts; HGF and HPLF) were
incubated for 48 h with various concentrations of crude plant
extract and the viable cell number was determined by the (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) method. The 50% cytotoxic concentration (CC50) was
determined from the dose-response curve. Tumor-specificity
(TS) was determined by the following equation: TS=mean
CC50 (normal cells)/mean CC50 (cancer cell lines). Metabolic
profiling techniques based on 1H nuclear magnetic resonance
(NMR) were applied to gain the chemical structural insight
for cytotoxicity induction. Results: Among 24 plant extracts,
Camptotheca acuminate leaf, a well-known source for
camptothecin, showed the highest TS value (88.3), followed by
Vitis s.p.p. (>3.5), Sasa veitchii (>2.3) and Phellodendron
amurense (>2.1), whereas other plant extracts showed much
lower TS value (<2). These cytotoxic extracts made cluster on
principal component analysis (PCA) score plot. Conclusion:
The TS value determined by the present method seems to
reflect the anti-tumor potential of each plant extract, while a
part of the cytotoxic compounds present in these extracts may
have common chemical structures.
Oral and oropharyngeal squamous cell carcinoma represents
a large, worldwide health burden with approximately
350,000 cases diagnosed annually (1). Most oral cancers are
diagnosed at an advanced stage accompanied by metastasis
to the lymph nodes located under the jaw and in the neck.
Possibly due to the late diagnosis of this disease or the poor-
tumor selectivity of conventional anti-tumor agents, the 5-
year survival rate of patients has remained at the level of
approximately 50% during the past 30 years. For squamous
cell carcinoma and most other types of oral cancer, surgery
and radiation remain as the sole therapy (2). Moreover,
surgery for oral cancers can be disfiguring and
psychologically-traumatic. Therefore, the development of
new treatment strategies and the early diagnosis of oral
cancer are of great importance (3). We have been searching
for new candidate materials derived from natural sources to
treat oral cancer. Actually, we herein investigated the effects
of crude plant extracts on the growth of oral normal (human
gingival fibroblast, HGF; periodontal ligament fibroblast,
HPLF) and tumor cells (oral squamous cell carcinoma HSC-
2 and HSC-4). 
Metabolic profiling techniques were used to find possible
correlations between the structural factors of a compound
and its biological activity (4, 5). Loading plot analysis
provides a useful strategy for the identification of biological
compounds. Nuclear magnetic resonance (NMR) is a
powerful method for such analysis because it allows the
simultaneous detection of diverse groups of primary and
secondary metabolites (6). In addition, NMR can give much
more structural information about metabolites than other
analytical techniques such as mass spectrometry (MS). We
have already reported the utilities of a metabolic profiling
method for evaluation of biological activities and growth
area of crude drugs (7, 8). In this study, we used 1H NMR-
based metabolic analysis to evaluate cytotoxicity of crude
plant extracts against oral squamous cell carcinoma and to
acquire chemical structural information of active compounds
included in cytotoxic materials.
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Materials and Methods
Materials. The following chemicals and reagents were obtained
from the indicated companies: Dulbecco’s modified Eagle medium
(DMEM) (Gibco BRL, Grand Island, NY, USA); fetal bovine serum
(FBS) (JRH Bioscience, Lenexa, KS, USA); 5-fluorouracil (5-FU)
(Kyowa, Tokyo, Japan); dimethyl sulfoxide (DMSO) (Wako Pure
Chem. Inc., Osaka, Japan); DMSO-d6 (Cambridge Isotope
Laboratories, Inc., MA, USA)
Plant materials. Crude plant extracts used in this study are listed in
Table I. These extracts have been already prepared and employed
for various screenings in our laboratory. All extracts were stored
at –30˚C before using. The original plants were mainly collected
in various places in Japan. The specimens were proved and
identified by Dr. Y. Shirataki and voucher specimens were also
deposited in the Department of Pharmacognosy and Natural
Medicines of Josai University.
NMR spectroscopy. 1H NMR spectra were recorded at room
temperature on a 400 MHz Agilent-400MR-vnmrs 400 spectrometer
(Agilent Technologies, CA, USA). Each spectrum consisted of
65,536 complex data points and a spectral width of 6,410.3Hz,
obtained by 16 scans with a repetition time of 5.0 sec and a
relaxation delay of 1.50 sec per scan. The detection pulse flip angle
was set at 45˚. 
NMR data reduction procedures and pattern recognition analysis.
Each NMR spectrum was regimented into 375 regions, 0.04 part
per million (ppm) wide, over the range –1.50 to 13.5 ppm. Each
segment of the spectral regions (bucket) was integrated. Any
integrated regions from 2.45 to 2.55 ppm that contained solvent
signals were eliminated from the data table and then the total data
were reduced to 372 regions. The remaining integral values of each
spectrum were normalized over 100 total summed integrals to
compensate for any differences in concentration between crude
drug extracts. Spectral processing was performed using ALICE 2
for Metabolome version 5.0 software (JEOL Ltd., Akishima,
Tokyo, Japan). 
Preparation of crude drug extracts. Twenty-four kinds of crude
plant extracts were prepared by extracting with MeOH under reflux
ANTICANCER RESEARCH 34: 4117-4120 (2014)
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Table I. Cytotoxicity of crude plant extracts (#1-24). The cells were incubated for 48 h without or with different concentrations of test samples and
the 50% cytotoxic concentration (CC50) value was determined by MTT. Each value represents the mean of triplicate assays. Note about No. 13-15
including 17 and 18: these samples were collected in different places, respectively. 
CC50 (μg/ml) 
Normal cells Oral squamous cell carcinoma
Mean±S.D. Mean±S.D.
No. Scientic name Part HGF HPLF (n=4) HSC-2 HSC-4 (n=4) TS
1 Odontioda Marie Noel ‘Velano’ Leaf 289 305 297±16 278 322 300±45 1.0
2 Odontioda Marie Noel ‘Velano’ Bulb 265 302 283±24 313 297 305±42 0.9
3 Odontioda Marie Noel ‘Velano’ Root 125 157 141±20 105 84 95±13 1.5
4 Odontoglossum Harvengtense ‘Tutu’ Leaf 271 302 286±19 277 272 274±19 1.0
5 Odontoglossum Harvengtense ‘Tutu’ Bulb 521 485 503±43 >500 400 >450 <1.1
6 Odontoglossum Harvengtense ‘Tutu’ Root 157 207 182±47 141 128 135±17 1.3
7 Pandanus amaryllifolius Leaf 335 357 346±157 258 246 252±35 1.4
8 Daucus carota Leaf 8 230 119±133 108 132 120±50 1.0
9 Vitis spp Root 370 >500 >435 128 118 123±9 >3.5
10 Camptotheca acuminata Leaf 283 335 309±30 4.3 2 3.5±1.6 88.3
11 Rhinacanthus nasutus Root 23 209 116±113 290 226 258±84 0.4
12 Phellodendron amurense Bark >500 >500 >500 300 244 272±37 >1.8
13 Sophora flavescens Root >500 >500 >500 >428 423 >425 ><1.2
14 Sophora flavescens Root 148 183 165±23 116 138 127±16 1.3
15 Sophora flavescens Root >500 >500 >500 >426 317 372±87> 1.3
16 Myrica rubra Twig 58 74 66±17 83 52 67±27 1.0
17 Myrica rubra Leaf <3.9 7 <5 23 14 18±5 <0.3
18 Myrica rubra Leaf <3.9 24 <14 111 89 100±59 <0.1
19 Nandina domestica Leaf 316 278 297±40 228 246 240±59 1.2
20 Euptelea polyandra Leaf 103 88 95±13 97 108 102±20 0.9
21 Sasa veitchii Leaf 415 >500 >458 198 197 197±12 >2.3
22 Theobroma cacao Fruit 452 >500 >476 >500 414 >457 ><1.0
23 Phellodendron amurense Bark >443 >500 >500 183 293 238±71 >2.1
24 Actinidia polygama Root >500 >500 >500 >500 >500 >500 ><1.0
Concentrations used: 0, 3.9, 7.8, 15,6, 31,25, 62,5, 125, 250, 500 μg/ml of each sample.
for 3 h to give the methanolic extracts. These extracts were
completely dried in vacuo and residues were dissolved in DMSO-d6
at 10 mg/ml in concentration for 1H NMR measurement and
dissolved in DMSO for cytotoxic evaluation.
Cell culture. Human oral squamous cell carcinoma cell lines (HSC-
2, HSC-4) were purchased from Riken Cell Bank, Tsukuba, Japan.
Normal human oral cells, gingival fibroblast (HGF) and periodontal
ligament fibroblast (HPLF), were prepared from periodontal tissues,
according to the guideline of the Intramural Ethic Committee (No.
A0808), after obtaining the informed consent from a 12-year-old
patient at the Meikai University Hospital (9). Since normal oral cells
have a limited lifespan of 43-47 population doubling levels (PDL)
(9), the cells at 8-15 PDL were used in this study. All the cells were
cultured in DMEM medium supplemented with 10% heat-
inactivated FBS, 100 U/ml penicillin G and 100 μg/ml streptomycin
sulfate. The normal cells were detached by 0.25% trypsin-0.025%
EDTA-2Na in phosphate-buffered saline (PBS) without Mg2+ and
Ca2+ (PBS(–)) and subcultured at a 1 : 4 split ratio once a week with
a medium change in between the subcultures. 
Assay for cytotoxic activity. The cells (3×103 cells/well, 0.1 ml/well)
were seeded in 96-microwell plates (Becton Dickinson and Company,
Franklin Lakes, NJ, USA) and incubated for 48 h to allow cell
attachment. Near-confluent cells were treated for 48 h with different
concentrations of the test compounds in a fresh medium. The relative
viable cell number of adherent cells was then determined by the (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
method (10). In brief, control and sample-treated cells were incubated
for 4 h with 0.2 mg/ml of MTT in the culture medium. After
removing the medium, the reaction product, formazan, was extracted
with DMSO and the absorbance (the relative viable cell number) was
measured at 540 nm by a microplate reader (Multiskan Bichromatic
Labsystems, Helsinki, Finland). The 50% cytotoxic concentration
(CC50) was determined from the dose–response curve. The tumor
specificity index (TS) was calculated by the following equation:
TS=mean CC50 (normal cells)/mean CC50 (all tumor cell lines).
Results
Cytotoxicity. Several kinds of crude plant extracts showed
higher cytotoxicity against human oral squamous cell
carcinoma compared with human oral normal cells, yielding
the tumor-specificity value of 1.0-88.3 (Table I). The extract
of #10 (Camptotheca acuminata) showed the highest tumor-
specificity, followed by #9 > #21 > #3 > #6 > #16.
1H NMR metabolomics. To give the chemical structural
feature of the active components, the crude plant extracts
Suzuki et al: New Cytotoxic Crude Materials Against Human Oral Squamous Cell Carcinoma
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Figure 1. The 1H NMR spectra were subjected to principal component analysis (PCA). PCA score plot of PC1-PC2, in which 372 variables were
equally accounted for in the data sets. The scores of PC1 and PC2 were 46.4, 31.8%, respectively. The circled dots show the sample exhibiting high
TS value.
were subjected to NMR-based metabolomics. The 1H NMR
spectra were subjected to principal component analysis
(PCA) (Figure 1). All 372 variables in the bucketed regions
(see Materials and Methods section) were equally accounted
for in the data sets. The PCA score plot of principal
component (PC) 1 (the greatest variance in the data) and PC2
(the second greatest variance in the data, orthogonal with
PC1) showed that the crude plant extracts showing high TS
value were gathered on PCA score plot (Figure 1, circled
dots indicated the sample showing high TS value). The
scores of PC1 and PC2 were 46.4, 31.8%, respectively.
Discussion 
The present study demonstrated that some methanolic plant
extracts showed tumor-specific cytotoxicity (TS=1.0-88.3)
(Table I). Among these extracts, the extract of #10
(Camptotheca acuminata) showed the highest tumor
specificity (TS=88.3). C. acuminata belongs to Nyssaceae and
distributed in the center of South China. It is well-known that
C. acuminata includes camptothecin, which has been the lead
compound for irinotecan. Irinotecan shows tumor-specific
cytotoxicity based on the inhibition of topoisomerase and is
used for the clinical treatment of lung and cervical cancer. The
present study demonstrated that the extract of C. acuminata
indicated the highest TS value, in agreement with our recent
report that camptothecin and SN-38, active metabolite of
irinotecan, showed the TS value of 2561 and 808, respectively
(11). This indicates that the TS value determined by the
present method seems to reflect the anti-tumor potential of
each plant extract, and may be a useful index for searching the
new anti-tumor agents, regardless of the cell types [epithelia
origin for oral squamous cell carcinoma (HSC-2, HSC-4) and
mesenchymal origin for normal oral cells (HGF, HPLF)].
Although both cytotoxicity and TS values are inferior to those
of #10, the extracts of #9 (Vitis spp), # 21 (Sasa veitchii), #3
(Odontioda Marie Noel ‘Velano’), #6 (Odontogrossum
Harvengtense ‘Tutu’) and #16 (Myrica rubra) indicated
slightly higher cytotoxicity against human oral squamous cell
carcinoma yielding modulate TS values. 
The values of PC1 and PC2 were used to give the
information concerning chemical structure of active
components in cytotoxic crude plant extracts. The score sum
of PC1 and PC2 was 78.2%, which was sufficient to identify
active components. Cytotoxic crude plant extracts indicating
modulate TS value formed a cluster on PCA score plot. These
results demonstrated that these extracts could contain
common compounds with similar structure(s) for expressing
cytotoxicity against tumor cells. Loading plot analysis and
direct comparison of 1H NMR spectra indicated that aromatic
signals on 1H NMR spectrum were detected commonly in
cytotoxic extracts. Based on these results, we are planning to
isolate and purify the active compounds and to elucidate those
structures included in cytotoxic crude extracts.
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